Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
amyotrophic lateral sclerosis
Biotech
Corcept's cortisol modulator fails to slow ALS decline in ph. 2
Corcept’s selective cortisol modulator failed to slow the progress of ALS and was linked to “substantially more gastrointestinal upset.”
James Waldron
Dec 12, 2024 7:05am
Dewpoint collects new pharma partner for preclinical ALS program
Dec 4, 2024 11:47am
PTC axes utreloxastat program after phase 2 ALS failure
Nov 27, 2024 4:45am
New York biotech files for bankruptcy
Nov 22, 2024 10:47am
Trace uses $101M series A to go after same ALS target as Lilly
Nov 12, 2024 7:00am
Synchron brain-computer interface clears year-long safety study
Oct 2, 2024 10:45am
